Inventiva completes a capital increase of € 8.2 million subscribed by leading US and European biotech investors

    NEXT STORY
    AveXis presents new data at EPNS continuing to show significant therapeutic benefit of Zolgensma® in prolonging event-free survival now up to 5 years of age in patients with spinal muscular atrophy (SMA) Type 1
    PREV STORY
    Annual Financial Report
    Subscribe to PM360
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    Sharps Compliance Reports Fiscal 2019 Third Quarter Results

    author_avatar
    NASDAQ Market News

    Capnography Devices Market Study, 2019-2025 – Rising Government Initiatives and Technological Advancements are Driving the Market

    author_avatar
    NASDAQ Market News

    Galena Biopharma to Report Third Quarter 2016 Financial Results and Provide a Corporate Update on Wednesday, November 9, 2016

    SAN RAMON, Calif., Oct. 26, 2016 (GLOBE NEWSWIRE) -- Galena Biopharma (NASDAQ:GALE), a biopharmaceutical ...

    author_avatar
    NASDAQ Market News